Welcome to CompanDX

CompanDX’s proprietary and industry leading proteomics and genomics bioinformatics technologies enable the discovery of novel biomarkers. A range of mass spectrometric and microarray gene expression interpretative services supports patient stratification, companion diagnostic development and guides clinical therapy decisions within the arena of personalised medicine.

CompanDX’s interpretative services have application across the pharmaceutical, biotechnology and healthcare sectors, with existing clients ranging from blue chip pharma to SMEs and clinical centres to academia. A flexible business model ensures partnering with CompanDX is uncomplicated, giving clients unparalleled access to leading edge analytical facilities and biomarker discovery tools.

CompanDX has developed extremely robust and reproducible analytical methods ensuring reproducibility in sample analysis, and bioinformatics tools which are setting the standard for the interrogation of large, non-linear high dimensional datasets. The result; delivery of biomarker signatures which are biologically relevant to the disease or clinical indications under investigation.

Applications include;

Identification of biomarkers and potential drug targets
Stratification of patients and clinical trial monitoring
Predictive failure of therapy and patient relapse
Development of companion diagnostics

CompanDX's technology enabling suite of "Distiller" algorithms includes;

In the arena of personalised medicine such biomarker signatures will allow with confidence the generation of genetic, proteomic, gene expression or microRNA companion diagnostics. This is particularly attractive in development of informative composite biomarkers predicting disease presence/absence or response to therapies where biomarkers are required to be highly sensitive, specific and accurate to direct "Go/No Go" decision making early during drug discovery in the clinic.

Whether used to guide prescription, recommend a drug for use in stratified patient populations or to evaluate genetic susceptibility relating to efficacy or dose, ComapnDX offers a completely new type of diagnostic paradigm with potential to significantly alter clinical management.

NEW- FAQ section available on the CompanDX website.

CompanDX brochure available.

Click the brochure icon to download a copy to your computer. To request a high-resolution copy via e-mail please complete the form on our Requests and Feedback page

Latest CompanDX News

June 17^th 2011: CompanDX and ResearchDx Announce Agreement.

CompanDX and ResearchDx have today announced a strategic partnership, allowing them to offer a full service capability to both discover and deliver novel MDx tests for clients in the healthcare setting.

To read the full transcript please click here or email us.

Thursday 07^th July 2011: CompanDX to present and exhibit at the SMi Pharmaceutical Conference “Biomarkers in Clinical Trials – Biomarkers in Cancer Drug Development”

This will take place at the Copthorne Tara Hotel, London (UK) on Monday 19th and Tuesday 20th September 2011.

The conference features a focussed agenda addressing all aspects of biomarker discovery, validation and usage; from PK/PD modelling to clinical trials and companion diagnostics to patient stratification.

For further information please click here and if you would like to arrange a meeting please email us.

Visit News Archive for more CompanDX news.

Privacy Statement